United Kingdom

Merck KGaA to Buy Silence Therapeutics for $1.1B

Is this a smart strategy or a debt-fueled overreach?

5 hours ago·Updated 1 hour ago

Merck KGaA to Buy Silence Therapeutics for $1.1B

Story

Above: A photo illustration of German company Merck KGaA's logo displayed on a smartphone. Image credit: Timon Schneider/SOPA Images/LightRocket/Getty Images

The Facts

Merck KGaA and British biotech firm Silence Therapeutics ("Silence") announced on Monday that they had entered into a definitive agreement for Merck KGaA to acquire Silence in an all-cash deal with an enterprise value of $1.1 billion and an equity value of about $1.3 billion.
Merck
Silence Therapeutics
The Wall Street Journal
City A.M.
Under the deal, Silence shareholders will receive $20 in cash per American depositary share, with each ADS representing three ordinary shares. The price marks a 130% premium to the stock's Oct. 16 close and an 82% premium to its 30-day average of $10.99.
Merck
Silence Therapeutics
The proposal also adds divesiran, a Phase 3-ready siRNA therapy for polycythemia vera, to Merck KGaA's pipeline. The drug, which has FDA Fast Track status, reportedly performed well in clinical trials, with an 88% responder rate in the Phase 2 SANRECO study.
Silence Therapeutics
Merck
Security holders representing roughly 14% of Silence's voting power agreed to support the takeover, which is expected to close in Q1 2027, pending shareholder approval, sanction by the High Court of Justice of England and Wales, and regulatory clearances.
Silence Therapeutics
Merck
In a statement, Merck KGaA CEO and Chair Kai Beckmann said the acquisition would strengthen the German business' ability to "serve patients with targeted specialty and rare diseases," pointing to a continued pipeline shift following last year's purchase of SpringWorks Therapeutics.
Silence Therapeutics
Merck
The agreement, which led Silence shares to rise nearly 5% in premarket trading, follows Merck KGaA's June deal to acquire Minneapolis-based Bio-Techne at an enterprise value of about $11.3 billion, Beckmann's first major transaction since becoming CEO in May.
Quartz
Seeking Alpha

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

This acquisition is a smart investment that benefits all parties involved. Shareholders will receive a strong cash premium, beating years of dilution and trial risk. Meanwhile, patients will soon have a new opportunity, as Merck KGaA has the scale and commercial reach to establish divesiran as a leading treatment for polycythemia vera.

Silence Therapeutics

Merck

Narrative B

Slapping a 130% premium on one clinical-stage asset is a rich price for a drug that still has to prove itself in late-stage trials. Gene-silencing has burned big pharma before, with an earlier billion-dollar bet later unloaded for a fraction of its cost. Funding the splurge with fresh debt, on top of an already heavy balance sheet, makes this move hard to defend.